Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Selinexor, selective inhibitor of nuclear export, for non-Hodgkin lymphoma

John Kuruvilla • 3 Oct 2015
iwNHL 2015
Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Selinexor

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, John Kuruvilla, MD, of Princess Margaret Cancer Centre, Toronto, Canada, discusses the early clinical activity of selinexor, an oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist, for the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and Richter’s transformation.

More from John Kuruvilla

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
1:06
Updates on the Phase Ib KEYNOTE-013 trial: pembrolizumab in NHL
John Kuruvilla • 12 Dec 2022
1:18
Hodgkin lymphoma highlights at ASH 2022 and future outlooks
John Kuruvilla • 12 Dec 2022
0:49
Abbv-319: a novel, CD19-GRM antibody-drug conjugate being explored for R/R B-cell malignancies
John Kuruvilla • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals